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ABSTRACT 27 
 28 
AIMS: Several studies have recently reported the detection of oncogenic human papillomaviruses 29 
(HPV) in human milk of a minority of lactating mothers. These findings raised safety concerns in 30 
the context of human donor milk banking given the potential risk of HPV transmission to recipient 31 
infants. The aim of this study was to investigate whether the Holder pasteurization, a procedure 32 
currently in use in human donor milk banks for milk pasteurization, completely inactivate high-risk 33 
and low risk HPV. METHODS: HPV pseudoviruses  (PsV) were generated, spiked into cell culture 34 
medium or donor human milk and subjected to thermal inactivation. HPV PsV infectivity and 35 
morphological integrity was analyzed by cell-based assay and by electron microscopy respectively. 36 
RESULTS: The Holder pasteurization completely inactivated the infectivity of high-risk (types 16 37 
and 18) and low-risk (type 6) HPV both in cell culture medium and in human milk causing PsV 38 
particles disassembly. CONCLUSIONS: The results presented here indicate that the Holder 39 
pasteurization is an efficient procedure to inactivate high-risk and low-risk HPV thus preventing the 40 
potential risk of their transmission through human donor milk. 41 
42 
INTRODUCTION 43 
Human papillomaviruses (HPV) are non-enveloped, double-stranded DNA viruses belonging to the 44 
Papillomaviridae family (15). HPV are classified into low-risk and high-risk groups according to 45 
their oncogenic potential. Low-risk HPV types, such as HPV-6 and HPV-11, can cause benign 46 
lesions of the anogenital areas, oral papillomas, conjunctival papillomas, as well as low-grade 47 
squamous intra-epithelial lesions of the cervix. Perinatally acquired low-risk HPV can also cause 48 
recurrent respiratory papillomatosis in infants and young children (19). Infection with high-risk 49 
HPV types (primarily types 16, 18, 31, and 45) can cause cervical cell abnormalities that are 50 
precursors to cancer (21). HPV types 16 and 18 cause about 70% of all cases of invasive cervical 51 
cancer worldwide, with type 16 having the greatest oncogenic potential (5). Moreover, they are also 52 
implicated in some head and neck cancers. The sexual activity is considered the primary route of 53 
transmission of high-risk HPV among adult individuals (18), however non-sexual routes are 54 
currently under investigation such as the vertical transmission through maternal milk. Indeed, in 55 
2008 a paper by Sarkola et al. (28) reported that 10 out of 223 breast-milk samples (4.5%) collected 56 
from Finnish women tested positive for HPV-16 raising the concern that high-risk HPV infections 57 
might be transmitted to infants via breast feeding. Recent studies by Cazzaniga et al., in Italy (9), 58 
Yoshida et al., in Japan (33) and Glenn et al., in Australia (13) confirmed the presence of high-risk 59 
HPV sequences in the milk of a minority of lactating women. By contrast, Mammas et al., could not 60 
detect any HPV sequences in milk samples from Greek women (22). To date, the possibility that 61 
HPV may be transmitted to infants through breast feeding causing clinically relevant infections 62 
remains to be investigated.  63 
Beside breast feeding, another context in which the potential risk of HPV transmission to recipient 64 
infants should be taken in to account is that of human donor milk banks. Donor breastmilk from 65 
milk banks is known to contribute to the survival and well being of premature and sick babies, 66 
particularly when born extremely premature and with very low birth weight. Moreover, it has been 67 
shown that where new milk banks are established, the provision of donor milk can increase the rates 68 
of breastfeeding on discharge from hospital of these babies (2).  In this context the microbiological 69 
safety of donor milk relies mainly on donor selection and on milk  pasteurization with the Holder 70 
method (62.5°C for 30 min) (17, 3, 1). Indeed, the Holder procedure has been shown to completely 71 
inactivate some viral pathogens that can cause clinically relevant infections to the infants when 72 
transmitted by maternal milk. These include the human immunodeficiency virus (HIV), the human 73 
T-lymphotrophic virus type I and II (HTLV-I and HTLV-II) and the human cytomegalovirus 74 
(HCMV) (12, 25, 31, 11, 14). By contrast, despite the concerns raised by the detection of oncogenic 75 
HPV in maternal milk, there are no data demonstrating the safety of Holder pasteurization for the 76 
inactivation of HPV. The difficulties to study HPV infectivity are due to the fact that these viruses 77 
cannot be cultured using conventional monolayer cell lines as they replicate exclusively in stratified 78 
squamous epithelial tissues (15). To overcome this obstacle, John Schiller and coworkers developed 79 
systems to efficiently produce high-titer HPV-based gene delivery vectors, known as HPV 80 
pseudoviruses (PsV) in cultured cell lines (6, 7). HPV PsV, are made of the two recombinant capsid 81 
protein L1 and L2 which assemble into particles that are indistinguishable from authentic HPV 82 
capsids and are capable of efficiently delivering reporter plasmids to a wide variety of cell lines. For 83 
this reason HPV PsV have rapidly become a useful tool for studying HPV infectivity (8, 10, 20). 84 
The aim of this study was to exploit the HPV PsV-based assays and electron microscopy to 85 
investigate the effects of Holder pasteurization on high-risk and low risk HPV. The data obtained 86 
demonstrate that Holder pasteurization completely inactivates HPV infectivity in cell culture 87 
medium and in human milk. 88 
89 
MATERIALS AND METHODS 90 
Milk samples. Breast milk samples were collected from healthy volunteer mothers with normal 91 
Papanicolau smear tests. Informed consent for breast milk donation was obtained from lactating 92 
mothers of newborns admitted in the Neonatal Care Unit of University of Torino. This study was 93 
approved by the Ethical Committee of the Italian Association of Human Milk Banks.  94 
Cells. The 293TT cell line, derived from human embryonic kidney cells transformed with the 95 
simian virus 40 (SV40) large T antigen, was cultured in Dulbecco’s modified Eagle’s medium 96 
(DMEM) (Gibco-BRL, Gaithersburg, MD) supplemented with heat-inactivated 10 % fetal calf 97 
serum (FCS; Gibco- BRL), Glutamax-I 1 % (Invitrogen, Carlsbad, CA) and nonessential amino 98 
acids 1 % (Sigma Aldrich, Steinheim, Germany). 293TT cells allow high levels of protein to be 99 
expressed from vectors containing the SV40 origin due to overreplication of the expression plasmid 100 
(Buck et al. 2004). Low-passage-number human embryonic lung fibroblasts (HELFs) were grown 101 
as monolayers in minimum essential medium (MEM) (SIGMA) supplemented with 10% fetal calf 102 
serum (FCS) (SIGMA), 1 mM sodium pyruvate and 1% antibiotic-antimycotic solution (Zell 103 
Shield, Minerva Biolabs GmbH, Berlin, Germany). 104 
Virus. A (BAC)-derived HCMV strain Towne incorporating the GFP sequence (23) was 105 
propagated on HELFs. The GFP marker facilitates identification of infected eukaryotic cells. Viral 106 
stocks were prepared by infecting HELFs at a virus-to-cell ratio of 0.01. The cells were incubated in 107 
MEM supplemented with 2% heat-inactivated FCS and cultured until a marked cytopathic effect 108 
was observed. Stocks were centrifugally clarified and frozen at −80°C. Virus titers were determined 109 
by plaque assay on HELFs.  110 
HPV PsV production.  Plasmids and 293TT cells used for pseudovirus (PsV) production were 111 
kindly provided by John Schiller (National Cancer Institute, Bethesda, MD). HPV-16, HPV-18 and 112 
HPV-6 PsVs were produced according to previously described methods (6). Briefly, 293TT cells 113 
were transfected with plasmids expressing the papillomavirus major and minor capsid proteins (L1 114 
and L2, respectively), together with a reporter plasmid expressing the secreted alkaline phosphatase 115 
(SEAP), or green fluorescent protein (GFP). Capsids were allowed to mature overnight in cell 116 
lysate; the clarified supernatant was then loaded on top of a density gradient of 27 to 33 to 39% 117 
Optiprep (Sigma-Aldrich, St. Louis, MO) at room temperature for 4 h. The material was centrifuged 118 
at 234,000 X g for 3.30 h at 16 °C in an SW50.1 rotor (Beckman Coulter, Inc., Fullerton, CA) and 119 
then collected by bottom puncture of the tubes. Fractions were inspected for purity in 10% sodium 120 
dodecyl sulfate (SDS)–Tris–glycine gels, titrated on 293TT cells to test for infectivity by SEAP  or 121 
GFP detection, and then pooled and frozen at -80 °C until needed. The L1 protein content of PsV 122 
stocks was determined by comparison with bovine serum albumin standards in Coomassie-stained 123 
SDS-polyacrylamide gels. 124 
HPV inactivation assays. For the SEAP-based assays, 293TT cells were preplated 24 h in advance 125 
in 96-well tissue culture-treated flat bottom plates at a density of 20000 cells/well in 100 µL of 126 
neutralization buffer (DMEM without phenol red, 10 % heat-inactivated fetal bovine serum, 1 % 127 
glutamate, 1 % nonessential aminoacids, 1 % antibiotic-antimycotic solution, and 10 mM Hepes). 128 
Diluited PsV stocks equivalent to a final concentration of approximately 1 ng/ml L1 or increased 129 
volumes of PsVs (equivalent to approximately 2 and 4 ng/ml L1) were incubated for 30 minutes in 130 
ice (4°C), at room temperature (25°C) or at increasing temperatures in a PCR thermocycler (37°C, 131 
45°C, 50°C, 55°C or 62.5°C) and then cooled at 4°C. The PsV solution (100 µL/well) was 132 
transferred onto the preplated cells and incubated for 72 h. After incubation, 25 µL of supernatant 133 
was harvested. The SEAP content in the supernatant was determined using a Great Escape SEAP 134 
Chemiluminescence Kit (BD Clon- tech, Mountain View, CA) as directed by the manufacturer. 135 
Thirty minutes after the addition of the substrate, samples were read using a Wallac 1420 Victor 136 
luminometer (PerkinElmer Life and Analytical Sciences, Inc., Wellesley, MA). The SEAP activity 137 
is expressed as counts per second (CPS). 138 
For the GFP-based assays diluited PsV stocks were incubated for 30 minutes at 4°C  or 62.5°C and 139 
then cooled at 4°C. The final concentration of PsV was approximately 1 ng/ml L1. The PsV 140 
solution was transferred onto the preplated cells and incubated at 37°C.  After 72 h the GFP-141 
expressing infected cells were observed on an inverted Zeiss LSM510 fluorescence microscope. 142 
HCMV inhibition assays. HELF cells were seeded into 96-well plates at a density of 104 143 
cells/well, and incubated at 37°C in a 5% CO2 atmosphere for 24 h. Cells were infected with GFP-144 
expressing HCMV, preincubated for 30 minutes at 4°C in ice or at 62.5°C in a PCR thermocycler, 145 
at a multiplicity of infection (MOI) of 1 for 2 hours at 37°C in MEM supplemented with 2% of 146 
heat-inactivated FCS. Then monolayers were washed three times and medium supplemented with 147 
10% FCS was replaced. Three days postinfection, cells infected were examined by an inverted 148 
Zeiss LSM510 fluorescence microscopy.  149 
Virus spiking experiments.  Raw milk samples from mothers were spiked with an inoculum of 150 
HPV-16 Psv (GFP) preparation (40 ng/ml L1) or cell-free culture supernatant of HCMV (GFP) (104 151 
pfu per milliliter raw milk) for Holder pasteurization experiments. 152 
Holder pasteurization. Each 100 L of spiked milk specimens were incubated for 30 minutes at 153 
62.5°C in a water bath, a procedure currently in use in human donor milk banks for milk 154 
pasteurization, and then cooled at 4°C. An additional sample of spiked milk was incubated for 30 155 
min at 4°C as a control. The virus-milk mixtures were then diluted in cell culture medium (1:2) and 156 
added to preplated cells to test virus infectivity, as previously described.  157 
Electron microscopy. An aliquot of diluted HPV-PsV preparation was allowed to adsorb for about 158 
3 min on carbon and formvar-coated grids and then rinsed several times with water. Grids were 159 
negatively stained with 0.5% uranyl acetate and excess fluid was removed with filter paper. 160 
Observations and photographs were made using a CM 10 electron microscope (Philips, Eindhoven, 161 
The Netherlands). 162 
Data analysis. Each data is the mean ± standard deviation of the mean for three determinations 163 
performed in duplicate. For the SEAP-based PsV neutralization assays the mean value obtained at 164 
different temperatures was expressed as a percentage of the mean value obtained at 4°C. Statistical 165 
analysis was performed by analysis of variance (ANOVA) followed by a Bonferroni test if P values 166 
showed significantly differences (P value < 0.05), using GraphPad Prism 5.00 (GraphPad 167 
Software).  168 
169 
RESULTS 170 
Characterization of purified HPV-16 PsV. For this study HPV-16 was chosen as a pivotal model 171 
because it is the genotype identified most often in human milk samples (28, 9, 33, 13). In 172 
preliminary experiments, the quality of the HPV-16 PsV preparations was assessed by SDS-PAGE 173 
and electron microscopy analysis. As shown in Fig. 1A, a major band migrating at 55 kDa was 174 
detected by SDS-PAGE followed by Coomassie brilliant blue staining (lane 1). The major band was 175 
confirmed to be the L1 major capsid protein by Western blot analysis with anti-L1 antibody (lane 176 
2). No L1-reactive proteolytic degradation products were observed at molecular masses below 55 177 
kDa demonstrating the quality of the preparation. Figure 1B shows an electron micrograph of the 178 
same PsV stock. The PsV particles exhibited an average diameter of 50 to 60 nm, similar to that of 179 
an authentic HPV capsid, and appeared as individual, well-assembled, icosahedral capsids. Similar 180 
results were obtained with the other HPV PsV types used in this study (data not shown). 181 
Effect of heat treatment on HPV-16 PsV infectivity in cell culture medium. To assess the effect 182 
of heat treatment on HPV infectivity, HPV-16 PsV diluted in cell culture medium, were exposed to 183 
increasing temperatures ranging from 4°C to 62.5°C for 30 minutes and then used to infect 293TT 184 
cell cultures. Viral infectivity was quantitatively assessed by measuring the SEAP levels in the cell 185 
culture supernatants. As shown in Fig. 2, PsV were stable at 4°C and 25°C, whereas exposure to 186 
45°C, 50°C and 55°C  resulted in a reduction of infectivity, although to different extents. By 187 
contrast, Holder pasteurization (62.5°C for 30 min.) completely abolished PsV infectivity. Of note, 188 
similar results were obtained when the Holder pasteurization was applied to PsV of an additional 189 
high-risk type such as HPV-18 and to a low-risk type such as HPV-6 (Fig. 3). Moreover, the effect 190 
of Holder pasteurization was not dependent on the PsV titer used as it was effective at HPV-16 PsV 191 
concentrations up to 4 ng/ml of L1 capsid protein (Fig. 4).  To rule out residual infectivity that 192 
could not be revealed by the SEAP assay, GFP-expressing PsV were used as they allow the 193 
detection of single infected cells by microscopy. As a control of the effectiveness of the Holder 194 
procedure, the assay was run in parallel with a GFP-expressing HCMV, a virus which is known to 195 
be completely inactivated by Holder pasteurization (11, 14). The results shown in Fig. 5 196 
demonstrate that no GFP-expressing cells could be detected in cell monolayers infected with HPV-197 
16 PsV (panel A) or HCMV (panel B) that underwent Holder pasteurization. By contrast, a high 198 
number of GFP-expressing cell are visible in monolayers infected with viruses maintained at 4°C 199 
for 30 min as positive controls.  200 
To further investigate the effect of the Holder pasteurization on HPV we analyzed the heat-treated 201 
HPV-16 PsV by electron microscopy. Fig. 6 compares a sample subjected to Holder pasteurization 202 
(panel B) to one maintained at 4°C for 30 min (panel A) as a control. As expected, in the control 203 
panel several PsV particles are clearly visible. At a higher magnification (panel A, inset) these 204 
particles appear as well assembled icosahedral capsids. By contrast, the analysis of the pasteurized 205 
PsV revealed that the heat treatment completely destroyed the structural integrity of the viral 206 
particles as no individual PsV can be observed (Fig. 6 panel B). Rarely, structures suggestive of 207 
denatured, disassembled capsids can be detected at a higher magnification (panel B, inset). 208 
Taken together these results demonstrates that HPV PsV are completely inactivated by Holder 209 
pasteurization in a acqueous matrix such as a cell culture medium. 210 
 211 
Effect of Holder pasteurization on HPV PsV in human milk. To determine the effectiveness of 212 
Holder pasteurization on HPV in human milk, raw milk samples from donor mothers were spiked 213 
with an inoculum of GFP expressing HPV-16 PsV or HCMV used a control. The inoculated milk 214 
was then pasteurized at 62.5°C for 30 minutes in a water bath, a procedure currently in use in 215 
human donor milk bank for milk pasteurization, or kept at 4°C. Diluted samples were then 216 
inoculated into cell monolayers and examined for GFP expression. As shown in Fig. 7, no GFP-217 
expressing cells could be detected in cell monolayers infected with pasteurized HPV-16 PsV (panel 218 
A) or HCMV (panel B). By contrast, a high number of GFP-expressing cells are visible in 219 
monolayers infected with viruses maintained at 4°C for 30 min as positive controls. Similar results 220 
were obtained when HPV-18 and HPV-6 PsV were used (data not shown). 221 
 222 
 223 
224 
DISCUSSION 225 
The potential risk of infection in recipient infants raised by the recent detection of high-risk HPV in 226 
human milk should be taken into account in the context of donor human milk banking. Currently, 227 
donor selection and pasteurization of milk are the most important procedures that guarantee the 228 
microbiological safety of human donor milk. Donor selection by serology or molecular diagnostic 229 
techniques does not seems suitable to prevent a potential risk of HPV transmission through milk as 230 
no concordance between cervical DNA detection and co-existent seropositivity was documented 231 
(26). Moreover, no correlation was found between mothers' cervical or oral HPV results and HPV 232 
detection in their breast milk (28, 22, 33). Besides, serology for HPV is not currently recommended 233 
in donor mothers screening (1, 16, 24). 234 
The Holder pasteurization is the most used and recommended method for the heat treatment of milk 235 
in donor human milk banks as it allows a good compromise between the nutritional quality of milk 236 
and its microbiological safety. Although its effectiveness to inactivate relevant viral pathogens 237 
transmitted through milk, like HIV, HTLV-I, HTLV-II and HCMV, is well established, no data are 238 
available for HPV.  Therefore, the aim of this study was to determine whether the Holder method 239 
completely inactivates HPV infectivity. We conducted our experiments both in cell culture medium 240 
and human milk since other researchers have demonstrated the protective effects of milk on non 241 
enveloped viruses such as hepatitis A virus (27, 4), poliovirus (30) and foot-and-mouth disease 242 
virus (32). We did demonstrate that Holder pasteurization abolishes completely the infectivity of 243 
high-risk HPV (i.e. HPV-16 and HPV-18) and low-risk HPV (i.e HPV-6) PsV in both matrices 244 
indicating that milk fat and the casein proteins do not exert any protective effect on HPV PsV 245 
particles. 246 
It has been shown that virus inactivation by pasteurization depends on denaturation of viral 247 
proteins, as well as disassembly of virus particles (29). To investigate the mechanism of HPV PsV 248 
inactivation by Holder pasteurization we examined heat-treated PsV by electron microscopy. 249 
According to what has been reported for other viruses (29) we observed that Holder pasteurization 250 
induced HPV PsV particle disassembly which result in the generation of non infectious subunits. 251 
Taken together, the results presented here indicate that the Holder pasteurization is an efficient 252 
procedure to inactivate high-risk and low-risk HPV thus preventing the potential risk of their 253 
transmission through human donor milk. 254 
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FIGURE LEGENDS  365 
 366 
Figure 1. Characterization of purified HPV-16 PsV. (A) An aliquot of purified PsV preparation was 367 
analyzed by SDS-PAGE with Coomassie brilliant blue staining (lane 1) or immunoblotting with an 368 
anti-L1 antibody (lane 2).  (B) Electron micrograph of a purified PV preparation. Bar 100 nm. 369 
 370 
Figure 2. Effect of different temperatures on HPV-16 PsV infectivity. PsV were incubated in cell 371 
culture medium at 4°C, 25°C, 37°C, 45°C, 50°C, 55°C or 62.5°C for 30 minutes and then used to 372 
infect 293TT cells for the measurement of SEAP expression. Results are given as the mean ± 373 
standard deviation of triplicates. The mean value was expressed as a percentage of the mean value 374 
obtained at 4°C. * P value < 0.05. 375 
 376 
Figure 3. Effect of Holder pasteurization  on HPV-18 and HPV-6 PsV infectivity. PsV were 377 
incubated in cell culture medium at 4°C, or 62.5°C for 30 minutes and then used to infect 293TT 378 
cells for the measurement of SEAP expression. Results are given as the mean ± standard deviation 379 
of triplicates. The mean value was expressed as a percentage of the mean value obtained at 4°C. P 380 
value < 0.05. 381 
 382 
Figure 4. Effect of Holder pasteurization on increasing concentrations of HPV-16 PsV ranging from 383 
1 to 4 ng/ml of L1 capsid protein. PsV were incubated in cell culture medium at 4°C, or 62.5°C for 384 
30 minutes and then used to infect 293TT cells for the measurement of SEAP expression (CPS: 385 
counts per second). Results are given as the mean ± standard deviation of triplicates. The mean 386 
value was expressed as a percentage of the mean value obtained at 4°C. P value < 0.05. 387 
 388 
Figure 5. Effect of Holder pasteurization on GFP expressing HPV-16 PsV (panel A ) or HCMV 389 
(panel B) in cell culture medium. PsV and HCMV were exposed to 4°C or to 62.5°C for 30 min and 390 
then used to infect 293TT or HELF cells respectively. Cells were analyzed by confocal laser 391 
scanning microscopy. The upper panels show the fluorescence images while the lower panels show 392 
phase-contrast images. 393 
 394 
Figure 6. Elecron microscopy of purified HPV-16 PsV. (A) An aliquot of purified PsV preparation 395 
was analyzed after incubation at 4°C for 30 min. Four distinct PsV particles are visible (indicated 396 
by arrows). The inset shows a well assembled icosahedral capsid at a higher magnification. (B) An 397 
aliquot of purified PsV preparation was analyzed after Holder pasteurization. No intact PsV are 398 
visible. The inset shows a structure suggestive of a dysassembled capsid at a higher magnification. 399 
Both images are at 120,000X magnification. This picture is representative of ten microscopic fields 400 
examined for each experimental condition. 401 
 402 
Figure 7. Effect of Holder pasteurization on GFP expressing HPV-16 PsV (panel A ) or HCMV 403 
(panel B) in human milk. PsV and HCMV were exposed to 4°C or to 62.5°C for 30 min and then 404 
used to infect 293TT or HELF cells respectively. Cells were analyzed by confocal laser scanning 405 
microscopy. The upper panels show the fluorescence images while the lower panels show phase-406 
contrast images. 407 
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